Celldex Therapeutics Inc (CLDX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Celldex Therapeutics Inc (CLDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10017
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:69
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Celldex Therapeutics Inc (Celldex) is a bio-pharmaceutical company that discovers, develops and commercializes targeted immunotherapy technologies and cancer-targeting biologicsfor the treatment of various types of cancers. The company’s developmental pipeline comprises therapeutic antibodies, antibody drug conjugates (ADCs), immune system modulators, vaccines and other protein-based therapeutics. Its key products in development include glembatumumabvedotin; Varlilumab; CDX-1401; CDX-3379; CDX-0158; CDX-301; and CDX-014. Celldex’s products find application in the treatment of various indications such as brain cancer, triple negative breast cancer, lymphoma/leukemia, melanoma, and renal cell carcinoma. It operates a manufacturing facility in Fall River, Massachusetts; and research laboratories in Massachusetts, New Jersey and Connecticut. Celldex is headquartered in Hampton, New Jersey, the US.

Celldex Therapeutics Inc (CLDX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Celldex Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 14
Venture Financing 14
Kolltan Pharma Raises US$60 Million In Series D Financing 14
Kolltan Pharma Raises US$25 Million In Series C Financing 16
Partnerships 17
Celldex Therapeutics Enters into Agreement with Roche 17
Licensing Agreements 18
Shanghai Henlius Biotech Enters into Licensing Agreement with Kolltan Pharma for KTN0216 18
Kolltan Pharma Enters into Licensing Agreement with Spirogen 19
Kolltan Pharma Enters Into Licensing Agreement With University of Toronto For Anti-KIT Antibodies And Related IP 20
Kolltan Pharma Enters Into Licensing Agreement With MedImmune 21
Kolltan Pharma Enters Into Licensing And Research Agreement With Children’s Hospital of Philadelphia For Pediatric Neuroblastoma Therapies 22
Equity Offering 23
Celldex Therapeutics Files Registration Statement for Public Offering of Shares 23
Celldex Therapeutics to Raise up to USD48.8 Million in Final Tranche of Public Offering of Shares 24
Celldex Therapeutics Raises USD200 Million in Public Offering of Shares 25
Kolltan Pharma Withdraws IPO 27
Celldex Therapeutics Completes Public Offering Of Shares For US$191.4 Million 28
Celldex Therapeutics Completes Public Offering Of Shares For US$104 Million 30
Celldex Therapeutics Completes Second Tranche Of Private Placement Of Shares For US$7.3 Million 32
Celldex Therapeutics Completes Third Tranche Of Private Placement Of Shares For US$21 Million 33
Celldex Therapeutics Completes Underwriters’ Exercise Of Over-Allotment Option For US$46 Million 35
Acquisition 37
Celldex Therapeutics Acquires Kolltan Pharma 37
Kolltan Pharma Acquires Xetrios Therapeutics 38
Celldex Therapeutics Inc – Key Competitors 39
Celldex Therapeutics Inc – Key Employees 40
Celldex Therapeutics Inc – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 43
Financial Announcements 43
Nov 07, 2018: Celldex provides corporate update and reports third quarter 2018 results 43
Aug 08, 2018: Celldex provides corporate update and reports second quarter 2018 results 45
May 10, 2018: Celldex Provides Corporate Update and Reports First Quarter 2018 Results 47
Mar 07, 2018: Celldex Provides Corporate Update and Reports Full Year 2017 Results 50
Nov 07, 2017: Celldex Reports Third Quarter 2017 Results 52
Aug 08, 2017: Celldex Reports Second Quarter 2017 Results 56
May 09, 2017: Celldex Reports First Quarter 2017 Results 58
Mar 14, 2017: Celldex Provides Corporate Update and Reports Full Year 2016 Results 60
Corporate Communications 62
Oct 03, 2017: Celldex Therapeutics Appoints Margo Heath-Chiozzi, M.D., as Senior Vice President, Regulatory Affairs 62
Sep 12, 2017: Celldex Announces Departure of Chief Medical Officer 63
Jun 16, 2017: Celldex Therapeutics Announces Additions to the Board of Directors and Senior Management Team 64
Mar 01, 2017: Celldex Therapeutics Announces Appointment to Board of Directors 65
Clinical Trials 66
Apr 20, 2018: Celldex Therapeutics presents data on CDX-1140 at AACR Annual Meeting 2018 66
Nov 30, 2017: Celldex Therapeutics Initiates Phase 1 Study of New Product Candidate CDX-1140 in Solid Tumors 67
May 17, 2017: Celldex Therapeutics to Present Clinical Results from Phase 2 Study of Glembatumumab Vedotin at 2017 ASCO Annual Meeting 68
Appendix 69
Methodology 69
About GlobalData 69
Contact Us 69
Disclaimer 69

List of Tables
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Celldex Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Celldex Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Kolltan Pharma Raises US$60 Million In Series D Financing 14
Kolltan Pharma Raises US$25 Million In Series C Financing 16
Celldex Therapeutics Enters into Agreement with Roche 17
Shanghai Henlius Biotech Enters into Licensing Agreement with Kolltan Pharma for KTN0216 18
Kolltan Pharma Enters into Licensing Agreement with Spirogen 19
Kolltan Pharma Enters Into Licensing Agreement With University of Toronto For Anti-KIT Antibodies And Related IP 20
Kolltan Pharma Enters Into Licensing Agreement With MedImmune 21
Kolltan Pharma Enters Into Licensing And Research Agreement With Children's Hospital of Philadelphia For Pediatric Neuroblastoma Therapies 22
Celldex Therapeutics Files Registration Statement for Public Offering of Shares 23
Celldex Therapeutics to Raise up to USD48.8 Million in Final Tranche of Public Offering of Shares 24
Celldex Therapeutics Raises USD200 Million in Public Offering of Shares 25
Kolltan Pharma Withdraws IPO 27
Celldex Therapeutics Completes Public Offering Of Shares For US$191.4 Million 28
Celldex Therapeutics Completes Public Offering Of Shares For US$104 Million 30
Celldex Therapeutics Completes Second Tranche Of Private Placement Of Shares For US$7.3 Million 32
Celldex Therapeutics Completes Third Tranche Of Private Placement Of Shares For US$21 Million 33
Celldex Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option For US$46 Million 35
Celldex Therapeutics Acquires Kolltan Pharma 37
Kolltan Pharma Acquires Xetrios Therapeutics 38
Celldex Therapeutics Inc, Key Competitors 39
Celldex Therapeutics Inc, Key Employees 40
Celldex Therapeutics Inc, Other Locations 41
Celldex Therapeutics Inc, Subsidiaries 41

List of Figures
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Celldex Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Celldex Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Celldex Therapeutics Inc (CLDX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Saponia D.D.
    Saponia D.D. - Strategy, SWOT and Corporate Finance Report Summary Saponia D.D. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • KELAG-Karntner Elektrizitats-Aktiengesellschaft:企業の戦略的SWOT分析
    KELAG-Karntner Elektrizitats-Aktiengesellschaft - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competito …
  • X4 Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary X4 Pharmaceuticals Inc (X4 Pharma) is a pharmaceutical company that develops novel therapeutics to treat cancer and rare diseases. The company’s lead drug candidate, X4P-001-LD, is in Phase 2/3 trial used for the treatment for patients with WHIM and other immunodeficiency disease. It also de …
  • Lotte Holdings Co. Ltd.:企業の戦略・SWOT・財務情報
    Lotte Holdings Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Lotte Holdings Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Enercon GmbH:企業の戦略的SWOT分析
    Enercon GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Altimmune Inc (ALT):製薬・医療:M&Aディール及び事業提携情報
    Summary Altimmune Inc (Altimmune), formerly Vaxin Inc is an immunotherapeutics company that develops vaccines and other biological products. The company’s products include nasovax, an intranasally administered recombinant influenza vaccine; and heptcell, an immunotherapy for patients chronically inf …
  • Embera NeuroTherapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Embera NeuroTherapeutics Inc (Embera) is a contract research company that discovers and develops new treatments. The company’s product includes EMB-001, a drug combination for the stress response system and specific brain functions that results in craving and improvement associated with thes …
  • Caretech Holdings Plc (CTH):企業の財務・戦略的SWOT分析
    Summary Caretech Holdings Plc (CareTech) is a children and adult care service provider. The company offers solution for adults and solution for children and young people. its adult care services includes learning disability, mental health, acquired brain injury, eating disorders, sensory impairments …
  • Becton Dickinson and Co (BDX):医療機器:M&Aディール及び事業提携情報
    Summary Becton Dickinson and Co (BD) is a medical technology company that manufactures and sells medical devices, reagents and instruments. Its major products include syringes and pen needles; intravenous catheters; infusion pumps and disposables; automated medication dispensing and supply managemen …
  • Biogen Inc (BIIB):医療機器:M&Aディール及び事業提携情報
    Summary Biogen Inc (Biogen) is a global biopharmaceutical company that discovers, develops and delivers drugs for the treatment of neurological and neurodegenerative diseases worldwide. The company’s marketed products include Avonex (interferon beta-1a), Tysabri (natalizumab), Tecfidera (dimethyl fu …
  • Camden Property Trust:企業の戦略・SWOT・財務情報
    Camden Property Trust - Strategy, SWOT and Corporate Finance Report Summary Camden Property Trust - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Briscoe Group Ltd (BGP):企業の財務・戦略的SWOT分析
    Briscoe Group Ltd (BGP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Vietnam National Oil and Gas Group-エネルギー分野:企業M&A・提携分析
    Summary Vietnam National Oil and Gas Group (Petrovietnam) is an oil and gas organization that offers oil and gas exploration and development services. The organization's services include oil and natural gas exploration and production, petroleum and financial services, processing of petrochemicals, r …
  • Lantheus Medical Imaging Inc:企業の戦略的SWOT分析
    Lantheus Medical Imaging Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Volta River Authority-エネルギー分野:企業M&A・提携分析
    Summary Volta River Authority (VRA) is a state-owned energy utility that generates, transmits, and distributes electricity. The authority produces power from solar, hydro, light crude oil, distillate fuel oil, and heavy fuel oil sources. It procures energy from Takoradi International Company Ltd; an …
  • Globus Medical Inc (GMED):企業の財務・戦略的SWOT分析
    Globus Medical Inc (GMED) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Teachers Mutual Bank Limited:企業の戦略的SWOT分析
    Teachers Mutual Bank Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • First Pacific Company Limited:企業の戦略・SWOT・財務分析
    First Pacific Company Limited - Strategy, SWOT and Corporate Finance Report Summary First Pacific Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • AnGes Inc (4563):製薬・医療:M&Aディール及び事業提携情報
    Summary AnGes Inc (AnGes) is a biopharmaceutical company which discovers and develops gene and nucleotide based drugs and reagents for use in functional analysis of genetic medication. The company specializes in research and development (R&D) and practical application of genetic medicine. It has two …
  • Ono Pharmaceutical Co., Ltd.:企業の戦略・SWOT・財務分析
    Ono Pharmaceutical Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Ono Pharmaceutical Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆